Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients

2019 ◽  
Vol 92 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Koji Nanmoku ◽  
Takahiro Shinzato ◽  
Taro Kubo ◽  
Toshihiro Shimizu ◽  
Takashi Yagisawa
Keyword(s):  
Bone Mineral Density ◽  
Kidney Transplant ◽  
Bone Mineral ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mineral Density ◽  
Bone Mineral Density Loss

FP734LOW BONE MINERAL DENSITY PREDICTS FRACTURE IN KIDNEY TRANSPLANT RECIPIENTS

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i293-i293
Author(s):  
Hanne Skou Jørgensen ◽  
Ivar Eide ◽  
Jens Bollerslev ◽  
Kristin Godang ◽  
Karsten Midtvedt ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Kidney Transplant ◽  
Bone Mineral ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mineral Density

scholarly journals Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients

2019 ◽  
Vol 95 (6) ◽  
pp. 1461-1470 ◽  
Author(s):  
Pieter Evenepoel ◽  
Kathleen Claes ◽  
Bjorn Meijers ◽  
Michaël R. Laurent ◽  
Bert Bammens ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Kidney Transplant ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
De Novo ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mineral Density ◽  
Turnover Markers

scholarly journals Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients

2010 ◽  
Vol 25 (2) ◽  
pp. E113-E123 ◽  
Author(s):  
Steven W. Ing ◽  
Loraine T. Sinnott ◽  
Sirisha Donepudi ◽  
Elizabeth A. Davies ◽  
Ronald P. Pelletier ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Kidney Transplant ◽  
Bone Mineral ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mineral Density ◽  
One Year

scholarly journals Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2361
Author(s):  
Hanne Skou Jørgensen ◽  
Ivar Anders Eide ◽  
Trond Jenssen ◽  
Anders Åsberg ◽  
Jens Bollerslev ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Fatty Acids ◽  
Lumbar Spine ◽  
Kidney Transplant ◽  
Bone Mineral ◽  
Controlled Trial ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mineral Density ◽  
Pufa Supplementation

Kidney transplant recipients are at high risk of progressive bone loss and low-energy fractures in the years following transplantation. Marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation may have beneficial effects on bone strength. The Omega-3 fatty acids in Renal Transplantation (ORENTRA) trial was an investigator initiated, randomized, placebo-controlled trial investigating the effects of marine n-3 PUFA supplementation after kidney transplantation. Effects of supplementation on bone mineral density (BMD) and calcium metabolism were pre-defined secondary endpoints. Adult kidney transplant recipients (n = 132) were randomized to 2.6 g marine n-3 PUFA supplement or olive oil (control) from 8 to 52 weeks post-transplant. Dual energy X-ray absorptiometry was performed to assess changes in bone mineral density of hip, spine, and forearm, as well as trabecular bone score (TBS) of the lumbar spine. Student’s t test was used to assess between-group differences. There were no differences in ΔBMD between the two groups (intervention vs. control) at lumbar spine (−0.020 ± 0.08 vs. −0.007 ± 0.07 g/cm², p = 0.34), total hip (0.001 ± 0.03 vs. −0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses. There was no difference in the change in TBS score (0.001 ± 0.096 vs. 0.009 ± 0.102, p = 0.62). Finally, no effect on biochemical parameters of mineral metabolism was seen. Results were similar when analyzed per protocol. In conclusion, we found no significant effect of 44 weeks of supplementation with 2.6 g of marine n-3 PUFA on BMD in kidney transplant recipients.

Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients

2020 ◽  
Vol 51 (6) ◽  
pp. 433-441
Author(s):  
Beini Lyu ◽  
Karen E. Hansen ◽  
Margaret R. Jorgenson ◽  
Brad C. Astor
Keyword(s):  
Bone Mineral Density ◽  
Proton Pump Inhibitor ◽  
Receptor Antagonist ◽  
Kidney Transplant ◽  
Bone Mineral ◽  
Proton Pump ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mineral Density ◽  
T Score

Background: In the general population, use of proton pump inhibitor (PPI) has been linked to higher risk of osteoporotic fractures. PPI is commonly prescribed in kidney transplant recipients (KTRs). However, the effect of PPI on osteoporosis in KTRs is largely unstudied. Methods: A total of 1,774 adult KTRs in the Wisconsin Allograft Recipient Database with at least one eligible bone mineral density (BMD) measurement at least 3 months after transplantation were included in the analyses. Associations between use of PPI and histamine-2 receptor antagonist (H2RA) at 3 months after transplantation and subsequent slope of T-score were assessed. Results: A total of 1,478 (83.3%) participants were using a PPI at 3 months after transplantation. Compared to the use of H2RA, use of PPI was not significantly associated with annualized slope of hip T-score (β = –0.0039, 95% CI –0.00497 to 0.0021) or annualized slope of spine T-score (β = –0.017, 95% CI –0.049 to 0.083) after adjustment for potential confounders. Similarly, no significant association between use of PPI and slope of T-score was observed when defining PPI/H2RA exposure as use within 6 months of the initial BMD measurement, or only including participants with at least 2 BMD measurements, or stratified by different age and sex. Conclusions: Use of PPI was not associated with an increased rate of BMD loss in KTRs. Our results support previous findings that PPI use does not have a significant effect on bone mineral loss.

Sign in / Sign up

Export Citation Format

Share Document